55
Participants
Start Date
October 25, 2013
Primary Completion Date
May 21, 2015
Study Completion Date
July 31, 2017
TAF
25 mg tablet administered orally once daily with food
Placebo
Tablets to match TAF administered orally once daily with food
E/C/F/TAF
150/150/200/10 mg STR administered orally once daily with food
Current failing ARV regimen
Participants will continue taking their current ARV regimen as prescribed in Part 1.
ATV
300 mg tablet administered orally once daily.
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok
Ramathibodi Hospital, Mahidol University, Bangkok
Salvador B Gautier Hospital - Infectious Diseases Department, Santo Domingo
Siriraj Hospital Department of Preventive and Social Medicine, Faculty of Medicine, Bangkok
Penn Presbyterian Medical Center, Philadelphia
Wake Forest University Health Sciences, Winston-Salem
Rowan Tree Medical, P.A., Wilton Manors
Triple O Research Institute, P.A., West Palm Beach
Midway Immunology and Research center, Ft. Pierce
Khon Kaen University, Khon Kaen
Chiang Mai University, Chiang Mai
Center For Prevention and Treatment of AIDS and Infectious Diseases, Saint Petersburg, Saint Petersburg
Regional state budget health agency Krasnoyarsk Regional Center for Prevention and Control of AIDS, Krasnoyarsk
Instituto Dominicano de Estudio Virologicos - IDEV, Santo Domingo
Joint Clinical Research Centre, Kampala
Lead Sponsor
Gilead Sciences
INDUSTRY